All Stories

  1. Association of insulin and GH/IGF-1 derangements and heart failure: a narrative review
  2. Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension
  3. Feature Reviews in Cardiovascular Diseases
  4. Aging of the vascular system: proposal of preventive intervention with known natural substances
  5. COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues
  6. Insulin Resistance with Associated Hyperinsulinemia as a Cause of the Development and Worsening of Heart Failure
  7. Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
  8. Chronically Increased Levels of Circulating Insulin Secondary to Insulin Resistance: A Silent Killer
  9. Insulin Resistance, a Risk Factor for Alzheimer’s Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach
  10. Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long
  11. Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction
  12. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
  13. A case of adverse reaction to booster dose of COVID-19 vaccination: could D-dimer elevation suggest increased clotting risk?
  14. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment
  15. Editorial: Methods in general cardiovascular medicine
  16. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
  17. Early Multi-Target Treatment of Mild-to-Moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin
  18. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview
  19. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
  20. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between Novembe...
  21. Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal
  22. Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19)
  23. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
  24. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial
  25. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension
  26. Response to letter by Wang Q et al. regarding article “Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension”
  27. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension
  28. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature
  29. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome
  30. Reply:
  31. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
  32. Insulin resistance: Is it time for primary prevention?
  33. The Importance of Tricuspid Regurgitation and Right Ventricular Overload in ICD/CRT Recipients: Beside the Left, beyond the Left
  34. Endocrine Alterations Are the Main Determinants of Cardiac Remodelling in Restrictive Anorexia Nervosa
  35. Cardiac involvement in active uncomplicated acromegaly
  36. A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
  37. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
  38. Letter by Fazio and Carlomagno Regarding Article, “Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population”
  39. Thyroid Hormones and Cardiovascular System: From Bench to Bedside
  40. Late Onset of Hypoxemia Due to a Pulmonary Arteriovenous Malformation During Selective Estrogen Receptor Modulator Therapy
  41. Cardiovascular and metabolic effects of Berberine
  42. Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure
  43. Long term combination treatment for severe idiopathic pulmonary arterial hypertension
  44. Usefulness of NT-proBNP in the assessment of patients with aortic or mitral regurgitation
  45. Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction
  46. The GH/IGF-1 Axis and Heart Failure
  47. Myocarditis and dilated cardiomyopathy: possible connections and treatments
  48. Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure
  49. Prehypertension and Elevated Risk of Cardiovascular Disease: Physiopathologic Mechanisms
  50. Association between post-ischemic forearm blood flow and blood pressure response to maximal exercise in well trained healthy young men
  51. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension
  52. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men
  53. Tadalafil in Primary Pulmonary Arterial Hypertension
  54. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning par...
  55. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade
  56. Peak exercise oxygen uptake and left ventricular systolic and diastolic function and arterial mechanics in healthy young men
  57. Effects of Thyroid Hormone on the Cardiovascular System
  58. Hyperthyroidism, Subclinical
  59. Subclinical Hypothyroidism and Cardiovascular Risk
  60. Subclinical Thyroid Dysfunction and the Heart
  61. Reactive hyperemia and cardiovascular performance in athletes regularly trained
  62. Prospective Evaluation of Hypertensive Patients with Carotid Kinking and Coiling: An Ultrasonographic 7-Year Study
  63. Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer
  64. The importance of using strict inclusion criteria in subclinical hypothyroid studies
  65. Effects of Subclinical Thyroid Dysfunction on the Heart
  66. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
  67. Patients with Subclinical Cushing’s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
  68. Subclinical Hypothyroidism and Cardiac Function
  69. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  70. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  71. Aldosterone Receptor Blockade in the Management of Heart Failure
  72. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  73. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  74. Mortality in elderly patients with subclinical hyperthyroidism
  75. Mortality in elderly patients with subclinical hyperthyroidism
  76. Growth hormone corrects vascular dysfunction in patients with chronic heart failure
  77. Impact of Hyperthyroidism and Its Correction on Vascular Reactivity in Humans
  78. Does the Growth Factor Approach Have a Future in the Treatment of Human Heart failure?
  79. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients*
  80. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients
  81. Growth hormone and cardiac function
  82. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence
  83. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  84. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  85. Heart Failure: Potential Benefit of Growth Hormone Therapy
  86. A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation
  87. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  88. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  89. Growth Hormone and the Heart
  90. Growth hormone as a potential future therapy for congestive heart failure
  91. Growth Hormone in Heart Failure
  92. Cardiac Effects of Growth Hormone in Physiology and in Heart Failure
  93. Doxorubicin‐induced cardiomyopathy treated with carvedilol
  94. Reentrant Atrioventricular Nodal Tachycardia Induced by Levothyroxine
  95. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy
  96. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  97. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  98. Growth hormone and heart performance: A novel mechanism of cardiac wall stress regulation in humans
  99. Prevalence of Carotid Kinking and Coiling in a Population at Risk
  100. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
  101. Growth Hormone in the Treatment of Dilated Cardiomyopathy
  102. Cardiovascular aspects in acromegaly: Effects of treatment
  103. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: Assessment with radionuclide angiography
  104. A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
  105. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy.
  106. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy
  107. Cardiac performance: Growth hormone enters the race
  108. Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency
  109. Optimal determination of right ventricular filling dynamics in systemic hypertension
  110. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta- blockade
  111. Pacemaker Malfunction Due to Subcutaneous Emphysema
  112. Growth Hormone and the Heart
  113. Growth hormone and the heart
  114. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement
  115. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly
  116. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine
  117. Cardiac Effects of Long Term Thyrotropin-Suppressive Therapy with Levothyroxine
  118. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
  119. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
  120. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
  121. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
  122. Platelet Aggregability in Patients with a VVI Pacemaker
  123. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study
  124. Capillary Blood Flow to the Skin of Forearm in Cirrhosis
  125. Influence of atenolol on the relationship between heart rate and qt interval in patients with exercise‐induced myocardial ischemia
  126. Pacemaker Malfunction Due to Subcutaneous Emphysema — A Case Report
  127. Evaluation, by Noninvasive Methods, of the Effects of Acute Loss of Thyroid Hormones on the Heart
  128. Follow‐Up of a Respiratory Rate Modulated Pacemaker
  129. Fourier Analysis in Patients with Different Pacing Modes
  130. Efficacy of Ticlopidine in the Prevention of Thromboembolic Events in Patients with VVI Pacemakers
  131. Cardiac function and sympathetic activity in young diabetics
  132. Cardiac function and sympathetic activity in young diabetics
  133. A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer
  134. Atenolol and Amiodarone: A Comparative Study of Their Anti-Ischaemic Effect
  135. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil
  136. Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study
  137. Obesity and cardiac function.